Study reveals new link between Down syndrome and Alzheimer's

November 2, 2015, Temple University
Domenico Praticò, M.D. Credit: The Lewis Katz School of Medicine at Temple University

Individuals with Down syndrome who survive into adulthood face the additional challenge of early-onset dementia, in which toxic amyloid plaques build up in the brain. The condition is strikingly similar to Alzheimer's disease, and as new work led by researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) shows, dementia in Down syndrome involves defects in a regulatory enzyme known as γ-secretase activating protein (GSAP), which also happens to malfunction in Alzheimer's disease.

In the field of Down syndrome research, the new findings are groundbreaking, and according to Domenico Praticò, MD, Professor in the Departments of Pharmacology and Microbiology and the Center for Translational Medicine at LKSOM and senior investigator on the study, the work could soon lead to the development of a specific GSAP-targeted therapy that is capable of safely mitigating dementia in Down syndrome. Previous γ-secretase inhibiting drugs failed in patients because of their high intrinsic toxicity.

The study, which appeared online in the Annals of Neurology, is the first to draw a connection between GSAP hyperactivity and excess processing of the Aβ precursor protein (APP) - the protein responsible for the final formation of - in Down syndrome. Dr. Praticò and colleagues made the discovery after examining donated tissue from the brains of deceased Down syndrome patients. Relative to postmortem brain tissue from healthy subjects, the samples from individuals with Down syndrome showed substantially elevated levels of both GSAP protein and its activity.

Dr. Praticò's team also found that GSAP hyperactivity was associated with abnormalities in the GATA1 transcription factor, which controls GSAP production. They demonstrated that when GATA1 activity was silenced in neurons that overexpressed APP, both GSAP levels and levels increased. Overexpression of GATA1, on the other hand, produced the opposite effect.

In Down syndrome, APP overexpression is extreme, reaching levels in the brain that are four to five times higher than normal. Its excess levels are a direct consequence of the triplicate copy of the 21st chromosome, which not only causes the syndrome in the first place but also houses the APP gene.

"The higher levels of APP in Down syndrome patients causes increased formation of amyloid beta peptides which then precipitate in the in the brain much earlier in life," Dr. Praticò explained. "Amyloid plaques begin to form in the brain of Down syndrome patients in the late teens and early 20s." Symptoms of dementia emerge in the following years.

The new findings could mark a turning point for Down syndrome survivors. "We've shown that GSAP inhibition reduces amyloid production, and because GSAP is specific to the formation of amyloid, without affecting other pathways, it should be a safe alternative to other strategies of a direct γ-secretase inhibition," Dr. Praticò said.

Dr. Praticò and colleagues already have access to a GSAP inhibitor. They plan next to investigate the effects of the agent in preclinical studies in mice. "We are very optimistic that our animal models will work," he said. "If they do, we will move to a clinical trial, where we hope to be able to reduce amyloid production safely and effectively."

Explore further: Down syndrome research untangles therapeutic possibilities for Alzheimer's

More information: Annals of Neurology: onlinelibrary.wiley.com/doi/10.1002/ana.24540/pdf

Related Stories

Down syndrome research untangles therapeutic possibilities for Alzheimer's

September 17, 2015
More than five million Americans are living with Alzheimer's disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients ...

New insight on why people with Down syndrome invariably develop Alzheimer's disease

October 23, 2014
A new study by researchers at Sanford-Burnham Medical Research Institute reveals the process that leads to changes in the brains of individuals with Down syndrome—the same changes that cause dementia in Alzheimer's patients. ...

Protein in the brain could be a key target in controlling Alzheimer's

January 25, 2012
A protein recently discovered in the brain could play a key role in regulating the creation of amyloid beta, the major component of plaques implicated in the development of Alzheimer's disease, according to researchers at ...

Overlooked for 30 years: Novel peptide plays role in Alzheimer's disease

August 31, 2015
A team led by Christian Haass has identified a novel peptide that plays a role in Alzheimer's disease: The previously overlooked eta-amyloid interferes with neuronal function and may antogonize beta-amyloid – a finding ...

Brain imaging changes in individuals with Down's may help advance Alzheimer's trials

April 14, 2015
Researchers have characterized three different brain imaging changes in individuals with Down syndrome, who are at very high risk for development of Alzheimer's disease, even before the onset of progressive memory and thinking ...

Recommended for you

Rate of dementia on the decline—but beware of growing numbers

April 17, 2018
The good news? The rate of older Americans with dementia is on the decline.

Research offers potential insight into Alzheimer's disease

April 16, 2018
Slightly elevated beta-amyloid levels in the brain are associated with increased activity in certain brain regions, according to a new study from the Center for Vital Longevity (CVL) at The University of Texas at Dallas.

Americans with a college education live longer without dementia and Alzheimer's

April 16, 2018
Education gives people an edge in their later years, helping them to keep dementia at bay and their memories intact, a new USC-led study has found.

Evidence mounts for Alzheimer's, suicide risks among youth in polluted cities

April 13, 2018
A University of Montana researcher and her collaborators have published a new study that reveals increased risks for Alzheimer's and suicide among children and young adults living in polluted megacities.

Improving brain function in Alzheimer's disease mouse model

April 11, 2018
Using two complementary approaches to reduce the deposits of amyloid-beta in the brain rather than either approach alone improved spatial navigation and memory in a mouse model of Alzheimer's disease. These findings suggest ...

Sleepless nights show ties to Alzheimer's risk

April 10, 2018
Even one night of lost sleep may cause the brain to fill with protein chunks that have long been linked to the development of Alzheimer's disease, a new study warns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.